Analysts Set Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Target Price at $28.00

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have earned a consensus recommendation of “Reduce” from the eight analysts that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $28.00.

A number of equities research analysts have recently weighed in on FMS shares. The Goldman Sachs Group downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. Erste Group Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 5th.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several large investors have recently modified their holdings of the stock. Pzena Investment Management LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 1.0% in the third quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock valued at $390,128,000 after purchasing an additional 153,870 shares in the last quarter. Morgan Stanley raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% in the 4th quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after buying an additional 942,497 shares in the last quarter. Todd Asset Management LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 5.2% in the 3rd quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock valued at $34,319,000 after buying an additional 64,311 shares in the last quarter. Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 8.3% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 816,200 shares of the company’s stock worth $21,491,000 after acquiring an additional 62,700 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 26.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 373,961 shares of the company’s stock worth $10,684,000 after acquiring an additional 78,956 shares in the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.1%

Shares of FMS stock opened at $24.44 on Wednesday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $20.94 and a 12-month high of $30.46. The company has a market capitalization of $14.17 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 0.77 and a beta of 0.90. The firm has a 50 day moving average price of $23.21 and a two-hundred day moving average price of $24.48. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high?flux dialyzers and bloodlines.